Researchers from Sapporo Medical University, School of Medicine in Hokkaido, Japan, recently completed and published the results of a study involving the antiviral drug favipiravir…
Recently, a private company approached the Thai government’s Department of Intellectual Property (DIP) to apply for a patent to produce what is now a generic…
TrialSite has chronicled many favipiravir studies and that numerous countries, including Russia, India and China, have accepted the drug as a COVID-19 treatment at least…
Japanese drug regulatory authorities failed to make a decision on whether favipiravir (Avigan) would be used as a treatment for COVID-19 alongside remdesivir (Gilead’s Veklury)…
Scotland has kicked off a favipiravir-based study investigating the efficacy and safety of that antiviral drug targeting COVID-19 cases in Caledonia. Organized by the Glasgow University…
The eastern African nation of Rwanda appears to be joining dozens of others nations worldwide and accepting Favipiravir as a treatment for COVID-19. The oral,…
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that its…
A Kuwait-based clinical trial sponsored by Indian generic drug producer Dr. Reddy’s Laboratory was recently terminated as the resulting data failed to evidence a statistically…
The Southeastern nation of Malaysia recently announced the planning for a major clinical trial to evaluate two low cost, widely available, orally administered generic drugs…
Yet another nation has opted to embrace the antiviral drug Favipiravir (Avigan) as a treatment for early onset COVID-19. Approved in Japan for influenza (and…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
